Detail akcie Cumberland Ph online

Business Summary: Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing new product candidates for rare diseases and other serious conditions. Its product candidates include Dyscorban (ifetroban), Vasculan (ifetroban) and Fibroban. Dyscorban (ifetroban) oral capsule is being developed for the treatment of the cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Vasculan (ifetroban) oral capsule has been developed for the treatment of systemic sclerosis (SSc), also known as scleroderma. It is a rare autoimmune disorder that results in a thickening of the skin and internal organs. Fibroban oral capsule is developed for the treatment of idiopathic pulmonary fibrosis (IPF). Its commercial products include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Acetadote (acetylcysteine) injection has been developed for the treatment of acetaminophen poisoning. Caldolor (ibuprofen) injection is developed for the treatment of pain and fever.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Cumberland Pharmaceuticals, Inc. revenues decreased 23% to $9.3M. Net loss applicable to common stockholders excluding extraordinary items increased from $1.7M to $6.4M. Revenues reflect Other segment decrease of 88% to $390K, Kristalose segment decrease of 41% to $2M. Higher net loss reflects Selling and Marketing increase of 20% to $5.1M (expense), Amortization increase of 24% to $1.3M (expense).